Mahnu Davar and Philip Desjardins Quoted in Regulatory Focus On FDA’s Response to Trump’s 10-for-1 Deregulatory Order
Life Sciences & Healthcare Regulatory partners Mahnu Davar and Philip Desjardins were recently quoted in Regulatory Focus's article, "Trump’s 10-for-1 order puts pressure on FDA to find regulations to nix." The article discussed the impact of President Trump’s executive order requiring the removal of 10 regulations, rules, or guidances for every new one issued, placing administrative pressure on federal health agencies.
Davar noted that the scale of the order is significant and that it places increased pressure on agencies such as the FDA to identify and eliminate existing rules, regulations, and guidances. While the FDA previously engaged in regulatory housekeeping under Trump’s 2017 deregulatory order, Davar pointed out that the latest mandate could have a far greater impact on which guidances move forward to finalization.
Desjardins echoed this concern, emphasizing the added pressure on the FDA to carefully evaluate the cost-benefit analysis of maintaining certain regulations. “One issue that will be important to watch is how the FDA adopts rules, regulations, and guidances that are congressionally mandated,” he said. He also noted that the executive order could affect the FDA’s ability to update critical regulatory processes, including its classification of medical devices.
